





Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/625,825		
		Filing Date	July 22, 2003		
		First Named Inventor	Anatoly E. Martynyuk		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	1	of	4	Attorney Docket Number	UF-281D2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	U1	4,279,917		Takami <i>et al.</i>	07-21-1981	All
PS	U2	4,491,589		Dell <i>et al.</i>	01-01-1985	All
PS	U3	4,604,286		Kawajiri	08-05-1986	All
PS	U4	5,605,818		Katsumata <i>et al.</i>	02-25-1997	All
PS	U5	6,013,672		Ye <i>et al.</i>	01-11-2000	All
PS	U6	6,084,084		Stormann <i>et al.</i>	07-04-2000	All
PS	U7	6,001,575		Huganir <i>et al.</i>	12-14-1999	All
PS	U8	6,362,226		Phillips, III <i>et al.</i>	03-26-2002	All
PS	U9	5,789,444		Choi <i>et al.</i>	08-04-1998	All
PS	U10	5,447,948		Seibyl <i>et al.</i>	09-05-1995	All
PS	U11	5,089,517		Choi <i>et al.</i>	02-18-1992	All
PS	U12	5,670,539		Richardson	09-23-1997	All
PS	U13	6,620,850	B2	Martynyuk <i>et al.</i>	09-16-2003	All
PS	U14	2003/0216472	A1	Martynyuk <i>et al.</i>	11-20-2003	All
PS	U15	10/489,807		Martynyuk <i>et al.</i> (patent application)	03-15-2004	All
	U16					
	U17					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	F1	WO	03/024443	A1	Univ. of Florida	03-27-2003	All	
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature	Phyllis Spivack	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/625,825	
			Filing Date	July 22, 2003	
			First Named Inventor	Anatoly E. Martynyuk	
			Group Art Unit	1614	
			Examiner Name	SPIVACK	
Sheet	2	of	4	Attorney Docket Number	UF-281D2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
PS	R1	CHIARONI, P. <i>et al.</i> "A multivariate analysis of red blood cell membrane transports and plasma levels of L-Tyrosine and L-Tryptophan in depressed patients before treatment and after clinical improvement" <i>Neuropsychobiology</i> , 1990, 23:1-7.		
PS	R2	DOLLINS, A.B. <i>et al.</i> "L-Tyrosine ameliorates some effects of lower body negative pressure stress" <i>Physiology &amp; Behavior</i> , 1995, 57(2):223-230.		
PS	R3	EATON, S.A. <i>et al.</i> "Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)- $\alpha$ -methyl-4-carboxyphenylglycine" <i>European Journal of Pharmacology-Molecular Pharmacology Section</i> , 1993, 244:195-197.		
PS	R4	GAGLIARDI, R.J. "Neuroprotection, excitotoxicity and NMDA antagonists" <i>Arq Neuropsiquiatr</i> , 2000, 58(2-B):583-588.		
PS	R5	GALLOWAY, G.P. <i>et al.</i> "A historically controlled trial of tyrosine for cocaine dependence" <i>Journal of Psychoactive Drugs</i> , July-September 1996, 28(3):305-309.		
PS	R6	GELENBERG, A.J. <i>et al.</i> "Neurotransmitter precursors for the treatment of depression" <i>Psychopharmacology Bulletin</i> , January 1982, 18(1):7-18.		
PS	R7	HAJAK, G. <i>et al.</i> "The influence of intravenous L-Tryptophan on plasma melatonin and sleep in men" <i>Pharmacopsychiat.</i> , 1991, 24:17-20.		
PS	R8	HELLER, B. <i>et al.</i> "Therapeutic action of D-phenylalanine in Parkinson's Disease" <i>Arzneim.-Forsch (Drug Res.)</i> , 1976, 26(4):577-579.		
PS	R9	HOLLMANN, M. <i>et al.</i> "Cloned Glutamate Receptors" <i>Annu. Rev. Neurosci.</i> , 1994, 17:31-108.		
PS	R10	KNOPFEL, T. <i>et al.</i> "Metabotropic glutamate receptors: Novel targets for drug development" <i>Journal of Medicinal Chemistry</i> , April 1995, 38(9):1417-1426.		
PS	R11	MAIESE, K. <i>et al.</i> "Group I and Group II metabotropic glutamate receptor subtypes provide enhanced neuroprotection" <i>Journal of Neuroscience Research</i> , 2000, 62:257-272.		
PS	R12	MEYER, J.S. <i>et al.</i> "Neurotransmitter precursor amino acids in the treatment of multi-infarct Dementia and Alzheimer's Disease" <i>Journal of the American Geriatrics Society</i> , July 1977, 25(7):289-298.		
PS	R13	OBRENOVITCH, T.P. "Excitotoxicity in neurological disorders--the glutamate paradox" <i>Int. J. Devl. Neuroscience</i> , 2000, 18:281-287.		

Examiner Signature	Phyllis Spivack	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/625,825	
			Filing Date	July 22, 2003	
			First Named Inventor	Anatoly E. Martynyuk	
			Group Art Unit	1614	
			Examiner Name	SPIVACK	
			Attorney Docket Number	UF-281D2	
Sheet	3	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
PS	R14	SAPOLSKY, R.M. "Cellular defenses against excitotoxic insults" <i>Journal of Neurochemistry</i> , 2001, 76:1601-1611.		
PS	R15	SCHOEPP, D.D. <i>et al.</i> "Metabotropic glutamate receptors in brain function and pathology" <i>TIPS</i> , January 1993, 14:13-20.		
PS	R16	SEKIYAMA, N. <i>et al.</i> "Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes" <i>British Journal of Pharmacology</i> , 1996, 117:1493-1503.		
PS	R17	WATKINS, J. <i>et al.</i> "Phenylglycine derivatives as antagonists of metabotropic glutamate receptors" <i>TIPS</i> , September 1994, 15:333-342.		
PS	R18	ZIPFEL, G.J. <i>et al.</i> "Neuronal apoptosis after CNS injury: The roles of glutamate and calcium" <i>Journal of Neurotrauma</i> , 2000, 17(10):857-869.		
PS	R19	BELARDINELLI, L. <i>et al.</i> "1,3-Dipropyl-8-[2-(5,6-Epoxy)Norbornyl]Xanthine, a Potent, Specific and Selective A <sub>1</sub> Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT <sub>1</sub> MF-2 Cells" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 275(3):1167-1176.		
PS	R20	CHOI, D.W. "Excitotoxic Cell Death" <i>J. Neurobiol.</i> , 1992, 23(9):1261-1276.		
PS	R21	DENNIS, D.M. <i>et al.</i> "Homologous Desensitization of the A <sub>1</sub> -Adenosine Receptor System in the Guinea Pig Atrioventricular Node" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 272(3):1024-1035.		
PS	R22	KOSTYUK, P.G. <i>et al.</i> "Effects of intracellular administration of L-tyrosine and L-phenylalanine on voltage-operated calcium conductance in PC12 pheochromocytoma cells" <i>Brain Res.</i> , 1991, 550:11-14.		
PS	R23	KRISTAL, J.H. <i>et al.</i> "NMDA Agonists and Antagonist as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders" <i>Harv. Rev. Psychiatry</i> , Sept.-Oct. 1999, 7(3):125-143.		
PS	R24	LIPTON, S.A. and P.A. ROSENBERG "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders" <i>N. Engl. J. Med.</i> , 1994, 330(9):613-622.		
PS	R25	MARTYNYUK, A.E. <i>et al.</i> "Blocking effect of intraperitoneal injection of phenylalanine on high-threshold calcium currents in rat hippocampal neurons" <i>Brain Res.</i> , 1991, 552:228-231.		
PS	R26	MARTYNYUK, A.E. <i>et al.</i> "Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes" <i>Cardiovasc. Res.</i> 1995, 30:668-675.		

Examiner Signature	<i>Phyllis Spivack</i>	Date Considered	8/5/03
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/625,825	
			Filing Date	July 22, 2003	
			First Named Inventor	Anatoly E. Martynyuk	
			Group Art Unit	1614	
Examiner Name	SPIVACK				
Attorney Docket Number	UF-281D2				
Sheet	4	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
PS	R27	MARTYNYUK, A.E. <i>et al.</i> "Hyperkalemia Enhances the Effect of Adenosine on I <sub>K,ADO</sub> in Rabbit Isolated AV Nodal Myocytes and on AV Nodal Conduction in Guinea Pig Isolated Heart" <i>Circulation</i> , 1999, 99:312-318.		
PS	R28	MOREY, T.E. <i>et al.</i> "Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart" <i>J. Pharmacol. Exp. Ther.</i> , 2001, 297(1):260-266.		
PS	R29	MOREY, T.E. <i>et al.</i> "Ionic Basis of the Differential Effects of Intravenous Anesthetics on Erythromycin-induced Prolongation of Ventricular Repolarization in the Guinea Pig Heart" <i>Anesthesiology</i> , 1997, 87:1172-1181.		
PS	R30	SEUBERT, C.N. <i>et al.</i> "Midazolam Selectively Potentiates the A <sub>2A</sub> but not A <sub>1</sub> receptor-mediated Effects of Adenosine" <i>Anesthesiology</i> , 2000, 92:567-577.		
PS	R31	TANAKA, H. <i>et al.</i> "The AMPAR subunit GluR2: still front and center-stage" <i>Brain Res.</i> , 2000, 886:190-207.		
PS	R32	WEISS, J.H. and S.L. SENSI "Ca <sup>2+</sup> -Zn <sup>2+</sup> permeable AMPA or kainite receptors: possible key factors in selective neurodegeneration" <i>Trends Neurosci.</i> , 2000, 23(8):365-371.		
PS	R33	ZIMA, A. <i>et al.</i> "Antagonism of the Positive Dromotropic Effect of Isoproterenol by Adenosine: Role of Nitric Oxide, cGMP-dependent camp-phosphodiesterase and Protein Kinase G" <i>J. Mol. Cell. Cardiol.</i> , 2000, 32:1609-1619.		
PS	R34	GLUSHAKOV, A.V. <i>et al.</i> "L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses" <i>J. Neurosci. Res.</i> , 2003, 72:116-124.		
PS	R35	GLUSHAKOV, A.V. <i>et al.</i> "Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria" <i>Molecular Psychiatry</i> , 2002, 7:359-367.		
PS	R36	LIECHTY, E.A. <i>et al.</i> "Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus" <i>J. Nutrition</i> , 1999, 129:1161-1166.		
	R37			
	R38			
	R39			

Examiner Signature	Phyllis Spivack	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/625,825		
		Filing Date	July 22, 2003		
		First Named Inventor	Anatoly E. Martynyuk		
		Group Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	1	of	4	Attorney Docket Number	UF-281D2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
PS	U1	4,279,917		Takami <i>et al.</i>	07-21-1981	All
PS	U2	4,491,589		Dell <i>et al.</i>	01-01-1985	All
PS	U3	4,604,286		Kawajiri	08-05-1986	All
PS	U4	5,605,818		Katsumata <i>et al.</i>	02-25-1997	All
PS	U5	6,013,672		Ye <i>et al.</i>	01-11-2000	All
PS	U6	6,084,084		Stormann <i>et al.</i>	07-04-2000	All
PS	U7	6,001,575		Huganir <i>et al.</i>	12-14-1999	All
PS	U8	6,362,226		Phillips, III <i>et al.</i>	03-26-2002	All
PS	U9	5,789,444		Choi <i>et al.</i>	08-04-1998	All
PS	U10	5,447,948		Seibyl <i>et al.</i>	09-05-1995	All
PS	U11	5,089,517		Choi <i>et al.</i>	02-18-1992	All
PS	U12	5,670,539		Richardson	09-23-1997	All
PS	U13	6,620,850	B2	Martynyuk <i>et al.</i>	09-16-2003	All
PS	U14	2003/0216472	A1	Martynyuk <i>et al.</i>	11-20-2003	All
PS	U15	10/489,807		Martynyuk <i>et al.</i> (patent application)	03-15-2004	All
	U16					
	U17					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
PS	F1	WO	03/024443	A1	Univ. of Florida	03-27-2003	All	
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature	Phyllis Spivack	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/625,825	
			Filing Date	July 22, 2003	
			First Named Inventor	Anatoly E. Martynyuk	
			Group Art Unit	1614	
			Examiner Name	SPINACK	
			Attorney Docket Number	UF-281D2	
Sheet	2	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
PS	R1	CHIARONI, P. et al. "A multivariate analysis of red blood cell membrane transports and plasma levels of L-Tyrosine and L-Tryptophan in depressed patients before treatment and after clinical improvement" <i>Neuropsychobiology</i> , 1990, 23:1-7.		
PS	R2	DOLLINS, A.B. et al. "L-Tyrosine ameliorates some effects of lower body negative pressure stress" <i>Physiology &amp; Behavior</i> , 1995, 57(2):223-230.		
PS	R3	EATON, S.A. et al. "Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-α-methyl-4-carboxyphenylglycine" <i>European Journal of Pharmacology-Molecular Pharmacology Section</i> , 1993, 244:195-197.		
PS	R4	GAGLIARDI, R.J. "Neuroprotection, excitotoxicity and NMDA antagonists" <i>Arq Neuropsiquiatr</i> , 2000, 58(2-B):583-588.		
PS	R5	GALLOWAY, G.P. et al. "A historically controlled trial of tyrosine for cocaine dependence" <i>Journal of Psychoactive Drugs</i> , July-September 1996, 28(3):305-309.		
PS	R6	GELENBERG, A.J. et al. "Neurotransmitter precursors for the treatment of depression" <i>Psychopharmacology Bulletin</i> , January 1982, 18(1):7-18.		
PS	R7	HAJAK, G. et al. "The influence of intravenous L-Tryptophan on plasma melatonin and sleep in men" <i>Pharmacopsychiat.</i> , 1991, 24:17-20.		
PS	R8	HELLER, B. et al. "Therapeutic action of D-phenylalanine in Parkinson's Disease" <i>Arzneim.-Forsch (Drug Res.)</i> , 1976, 26(4):577-579.		
PS	R9	HOLLMANN, M. et al. "Cloned Glutamate Receptors" <i>Annu. Rev. Neurosci.</i> , 1994, 17:31-108.		
PS	R10	KNOPFEL, T. et al. "Metabotropic glutamate receptors: Novel targets for drug development" <i>Journal of Medicinal Chemistry</i> , April 1995, 38(9):1417-1426.		
PS	R11	MAIESE, K. et al. "Group I and Group II metabotropic glutamate receptor subtypes provide enhanced neuroprotection" <i>Journal of Neuroscience Research</i> , 2000, 62:257-272.		
PS	R12	MEYER, J.S. et al. "Neurotransmitter precursor amino acids in the treatment of multi-infarct Dementia and Alzheimer's Disease" <i>Journal of the American Geriatrics Society</i> , July 1977, 25(7):289-298.		
PS	R13	OBRENOVITCH, T.P. "Excitotoxicity in neurological disorders--the glutamate paradox" <i>Int. J. Devl. Neuroscience</i> , 2000, 18:281-287.		

Examiner Signature	Phyllis SPINACK	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/625,825
		Filing Date	July 22, 2003
		First Named Inventor	Anatoly E. Martynyuk
		Group Art Unit	1614
		Examiner Name	SPIVACK
		Attorney Docket Number	UF-281D2
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS	R14	SAPOLSKY, R.M. "Cellular defenses against excitotoxic insults" <i>Journal of Neurochemistry</i> , 2001, 76:1601-1611.	
PS	R15	SCHOEPP, D.D. <i>et al.</i> "Metabotropic glutamate receptors in brain function and pathology" <i>TIPS</i> , January 1993, 14:13-20.	
PS	R16	SEKIYAMA, N. <i>et al.</i> "Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes" <i>British Journal of Pharmacology</i> , 1996, 117:1493-1503.	
PS	R17	WATKINS, J. <i>et al.</i> "Phenyglycine derivatives as antagonists of metabotropic glutamate receptors" <i>TIPS</i> , September 1994, 15:333-342.	
PS	R18	ZIPFEL, G.J. <i>et al.</i> "Neuronal apoptosis after CNS injury: The roles of glutamate and calcium" <i>Journal of Neurotrauma</i> , 2000, 17(10):857-869.	
PS	R19	BELARDINELLI, L. <i>et al.</i> "1,3-Dipropyl-8-[2-(5,6-Epoxy)Norbornyl]Xanthine, a Potent, Specific and Selective A <sub>1</sub> Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT <sub>1</sub> MF-2 Cells" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 275(3):1167-1176.	
PS	R20	CHOI, D.W. "Excitotoxic Cell Death" <i>J. Neurobiol.</i> , 1992, 23(9):1261-1276.	
PS	R21	DENNIS, D.M. <i>et al.</i> "Homologous Desensitization of the A <sub>1</sub> -Adenosine Receptor System in the Guinea Pig Atrioventricular Node" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 272(3):1024-1035.	
PS	R22	KOSTYUK, P.G. <i>et al.</i> "Effects of intracellular administration of L-tyrosine and L-phenylalanine on voltage-operated calcium conductance in PC12 pheochromocytoma cells" <i>Brain Res.</i> , 1991, 550:11-14.	
PS	R23	KRYSTAL, J.H. <i>et al.</i> "NMDA Agonists and Antagonist as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders" <i>Harv. Rev. Psychiatry</i> , Sept.-Oct. 1999, 7(3):125-143.	
PS	R24	LIPTON, S.A. and P.A. ROSENBERG "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders" <i>N. Engl. J. Med.</i> , 1994, 330(9):613-622.	
PS	R25	MARTYNYUK, A.E. <i>et al.</i> "Blocking effect of intraperitoneal injection of phenylalanine on high-threshold calcium currents in rat hippocampal neurons" <i>Brain Res.</i> , 1991, 552:228-231.	
PS	R26	MARTYNYUK, A.E. <i>et al.</i> "Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes" <i>Cardiovasc. Res.</i> 1995, 30:668-675.	

Examiner Signature	<i>Ruthlis Spivack</i>	Date Considered	8/5/05
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/625,825
				Filing Date	July 22, 2003
				First Named Inventor	Anatoly E. Martynyuk
				Group Art Unit	1614
				Examiner Name	SPIVACK
				Attorney Docket Number	UF-281D2
Sheet	4	of	4		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
PS	R27	MARTYNYUK, A.E. <i>et al.</i> "Hyperkalemia Enhances the Effect of Adenosine on I <sub>K,ADO</sub> in Rabbit Isolated AV Nodal Myocytes and on AV Nodal Conduction in Guinea Pig Isolated Heart" <i>Circulation</i> , 1999, 99:312-318.		
PS	R28	MOREY, T.E. <i>et al.</i> "Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart" <i>J. Pharmacol. Exp. Ther.</i> , 2001, 297(1):260-266.		
PS	R29	MOREY, T.E. <i>et al.</i> "Ionic Basis of the Differential Effects of Intravenous Anesthetics on Erythromycin-induced Prolongation of Ventricular Repolarization in the Guinea Pig Heart" <i>Anesthesiology</i> , 1997, 87:1172-1181.		
PS	R30	SEUBERT, C.N. <i>et al.</i> "Midazolam Selectively Potentiates the A <sub>2A</sub> but not A <sub>1</sub> receptor-mediated Effects of Adenosine" <i>Anesthesiology</i> , 2000, 92:567-577.		
PS	R31	TANAKA, H. <i>et al.</i> "The AMPAR subunit GluR2: still front and center-stage" <i>Brain Res.</i> , 2000, 886:190-207.		
PS	R32	WEISS, J.H. and S.L. SENSITIVE "Ca <sup>2+</sup> -Zn <sup>2+</sup> permeable AMPA or kainite receptors: possible key factors in selective neurodegeneration" <i>Trends Neurosci.</i> , 2000, 23(8):365-371.		
PS	R33	ZIMA, A. <i>et al.</i> "Antagonism of the Positive Dromotropic Effect of Isoproterenol by Adenosine: Role of Nitric Oxide, cGMP-dependent camp-phosphodiesterase and Protein Kinase G" <i>J. Mol. Cell. Cardiol.</i> , 2000, 32:1609-1619.		
PS	R34	GLUSHAKOV, A.V. <i>et al.</i> "L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses" <i>J. Neurosci. Res.</i> , 2003, 72:116-124.		
PS	R35	GLUSHAKOV, A.V. <i>et al.</i> "Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria" <i>Molecular Psychiatry</i> , 2002, 7:359-367.		
PS	R36	LIECHTY, E.A. <i>et al.</i> "Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus" <i>J. Nutrition</i> , 1999, 129:1161-1166.		
	R37			
	R38			
	R39			

Examiner Signature	Phyllis Spivack	Date Considered	8/5/05
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.